stockrowAmylyx Pharmaceuticals, Inc.
AMLX Healthcare Drug Manufacturers Specialty & Generic
Amylyx Pharmaceuticals, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $87.4 million, down 77.1% from fiscal 2023.
- Revenue
- −100.6%
- EPS
- +15.2%
- Free cash flow
- −24.5%
Quarter to June 2026, against a year earlier
Follow AMLX
Alert me
Amylyx Pharmaceuticals, Inc. (AMLX) Current ratio
Amylyx Pharmaceuticals, Inc.'s current ratio at the end of the quarter to 30 June 2026 was 12.1×, down 2.1× from fiscal 2025 (14.3×). Over the past ten years it has ranged from 1.9× (fiscal 2020) to 14.3× (fiscal 2025) — the current reading is the highest in ten years. That is above the Drug Manufacturers Specialty & Generic industry median of 2.4× and above the Healthcare sector median of 3.1×.
Current ratio, annual
Embed this chart
Annual newest first
| Period | Current ratio | Change |
|---|---|---|
| FY2025 | 14.3× | 113.93% |
| FY2024 | 6.7× | 17.74% |
| FY2023 | 5.7× | (30.92%) |
| FY2022 | 8.2× | 35.90% |
| FY2021 | 6.0× | 224.06% |
| FY2020 | 1.9× | — |
Quarterly newest first
| Period | Current ratio | Change |
|---|---|---|
| Jun 2026 | 12.1× | (32.11%) |
| Mar 2026 | 17.9× | 25.13% |
| Dec 2025 | 14.3× | 4.12% |
| Sep 2025 | 13.7× | 57.07% |
| 16 more quarters | Free account |
Against its own ten years
Current ratio against peers
| Company | Current ratio |
|---|---|
| AMLX Amylyx Pharmaceuticals, Inc. | 12.1× |
| RGC Regencell Bioscience Holdings Limited compare | 10.8× |
| HCM HUTCHMED (China) Limited Sponsored ADR compare | 5.6× |
| TRLV Trulieve Cannabis Corp. compare | 5.5× |
| PBH Prestige Consumer Healthcare Inc. compare | 2.9× |
| PRGO Perrigo Company plc compare | 2.4× |
| LQDA Liquidia Corporation compare | 2.3× |
| HIMS Hims & Hers Health, Inc. compare | 0.9× |
| SUPN Indivior Pharmaceuticals Inc. compare | 0.6× |
| Drug Manufacturers Specialty & Generic industry median | 2.4× |
| Healthcare sector median | 3.1× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)
More on AMLX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement